Why did HURA's EPS remain flat in Q2 2024?

TuHURA Biosciences' (HURA) EPS remained flat in Q2 2024 due to a combination of factors:

1. **Revenue and Expense Balance**: TuHURA Biosciences reported a net income of -$2.32 million for Q2 2024, with no available data on revenue for the quarter. However, the company's research and development (R&D) expenses were reported at $101,000 for the same period. The absence of marketing and management expenses suggests that the company's financials may be influenced by the costs associated with R&D. Without revenue data, it's challenging to determine the full extent of the company's financial performance, but the negative net income indicates that the costs, including R&D, exceeded the income generated during the quarter.

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|HURA|HURA.O|TuHURA Biosciences|2024 Q1|35.552654482158395|-2962000|186|
|HURA|HURA.O|TuHURA Biosciences|2024 Q2|70.38216560509554|-1023000|186|

|code|Ticker|Name|Date|R&D Expenses|R&D Expenses YoY|market_code|
|---|---|---|---|---|---|---|
|HURA|HURA.O|TuHURA Biosciences|2024 Q1|1859000|-41.374960580258595|186|
|HURA|HURA.O|TuHURA Biosciences|2024 Q2|111000|-94.60903351141332|186|

In conclusion, the flat EPS in Q2 2024 for TuHURA Biosciences can be attributed to the balance between the company's R&D expenses and the absence of revenue data, which makes it difficult to determine the full financial picture of the company during that quarter.